Easy to use for localized pain described as shooting, burning, tingling and stabbing. Neuragen Cream is a topical cream for temporary relief of pain described as shooting, burning, tingling and stabbing. Neuragen Cream contains the same ingredients as Neuragen Oil, but many people find the cream format easier to apply to the site of pain. Available in a 4 oz. tube.
Cautions
For topical use only, do not take internally. Avoid contact with eyes. Discontinue use if skin irritation develops. Keep out of reach of children. In case of accidental ingestion, seek professional assistance. Store at controlled room temperature (59-86 degrees F). May stain some fabrics or finishes. Due to the nature of the botanical extracts used, Neuragen has a strong floral aroma.
Three clinical trials of Neuragen have been completed to date with 160 patients.
Effective for >80% of Sufferers
The graphs below depict a double blind placebo controlled trial by independent researchers at Louisiana State University. 60 subjects experiencing all-cause neuropathic foot pain (top) and a sub group of diabetic neuropathy (bottom) were treated with Neuragen. In both cases greater than 80% of patients received significant relief.
Effective for up to 8 Hours
40 subjects with all-cause neuropathic pain in the feet were treated in a LSU double blind placebo controlled trial. The graph below represents the average pain level for all participants before treatment (time=0) and for up to 9 hours after treatment with either Neuragen (blue drops) or placebo (grey triangles). Pain relief with Neuragen was statistically significant over placebo and for up to 8 hours in duration.
Highly Effective on 63% of Sufferers
Another commonly accepted way to analyze data from pain trials is to compare the number of patients who received at least a 50% reduction in pain level vs. placebo. As shown below, 63% of subjects receiving Neuragen benefited from a 50% or greater reduction in pain, vs. only 15% in the placebo group.
Three clinical trials of Neuragen have been completed to date with 160 patients.